Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa

Thrombosis Research

Volumn 131, Issue 5, 2013, Pages 450-456

  Kaku, Seiji ^a   Suzuki, Mami ^a   Saitoh, Minori ^a   Funatsu, Toshiyuki ^a   Uemura, Toshio ^a   Suzuki, Ken Ichi ^a   Iwatsuki, Yoshiyuki ^a   Kawasaki, Tomihisa ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

antidote; bleeding; factor Xa; thrombosis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DAREXABAN; FERROUS CHLORIDE; GLUCURONIDE; NOVO NORSIDK A S; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG INHIBITION; IN VITRO STUDY; LUNG EMBOLISM; MALE; METABOLITE; MORTALITY; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTHROMBIN TIME; THROMBOSIS; THROMBUS; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; AZEPINES; BENZAMIDES; DISEASE MODELS, ANIMAL; FACTOR VIIA; HEMORRHAGE; HUMANS; MALE; MICE; MICE, INBRED ICR; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBOSIS; WARFARIN;

EID: 84877786724     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.03.016     Document Type: Article

References (25)

1. S. Schulman The role of ximelagatran in the treatment of venous thromboembolism Pathophysiol Haemost Thromb 34 Suppl. 1 2005 18 24
2. J. Ansell, and D. Bergqvist Current options in the prevention of thromboembolic disease Drugs 64 Suppl. 1 2004 1 5
3. G.A. Soff A New Generation of Oral Direct Anticoagulants Arterioscler Thromb Vasc Biol 32 2012 569 574
4. Y. Iwatsuki, T. Sato, Y. Moritani, T. Shigenaga, M. Suzuki, and T. Kawasaki Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor Eur J Pharmacol 673 2011 49 55
5. T. Funatsu, Y. Iwatsuki, and S. Kaku Darexaban has high sensitivity in the prothrombin time clotting test J Thromb Haemost 10 2012 703 705
6. S. Kaku, T. Uemura, M. Saitoh, K.I. Suzuki, Y. Iwatsuki, and T. Funatsu Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis Eur J Pharmacol 699 2012 40 47
7. T. Funatsu, A. Yamashita, S. Kaku, Y. Iwatsuki, and Y. Asada Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models Thromb Haemost 108 2012 896 902
8. B.I. Eriksson, A.G. Turpie, M.R. Lassen, M.H. Prins, G. Agnelli, and P. Kalebo Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2) J Thromb Haemost 8 2010 714 721
9. B.I. Eriksson, A.G. Turpie, M.R. Lassen, M.H. Prins, G. Agnelli, and P. Kalebo A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery J Thromb Haemost 5 2007 1660 1665
10. M. Sakon, and M. Nakamura Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study Thromb Res 130 2012 e52 e59
11. P.G. Steg, S.R. Mehta, J.W. Jukema, G.Y. Lip, C.M. Gibson, and F. Kovar RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 2011 2541 2554
12. A. Godier, A. Miclot, B. Le Bonniec, M. Durand, A.M. Fischer, and J. Emmerich Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 2012 94 102
13. T. Fukuda, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents Thromb Haemost 107 2012 253 259
14. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
15. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J.L. Crackowski, and G. Pernod Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers Thromb Haemost 108 2012 217 224
16. G. Lu, F.R. DeGuzman, S. Lakhotia, S.J. Hollenbach, D.R. Phillips, and U. Sinha Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors ASH Annual Meeting Abstracts 112 2008 983
17. J. Toth, G. Gan, J. van Ryn, H. Dursema, J. Isler, and K. Coble Reversal of Dabigatran's Anticoagulant Activity in the Monkey by a Specific Antidote and Pharmacokinetic and Pharmacodynamic Modeling ASH Annual Meeting Abstracts 120 2012 22
18. J. van Ryn, T. Litzenburger, G. Gan, K. Coble, and J. Schurer In Vitro Characterization, Pharmacokinetics and Reversal of Supratherapeutic Doses of Dabigatran-Induced Bleeding in Rats by a Specific Antibody Fragment Antidote to Dabigatran ASH Annual Meeting Abstracts 120 2012 3418
19. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
20. X. Wang, P.L. Smith, M.Y. Hsu, M.L. Ogletree, and W.A. Schumacher Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor J Thromb Haemost 4 2006 403 410
21. R.J. Broersma, L.W. Kutcher, E.F. Heminger, J.L. Krstenansky, and F.N. Marshall Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals Thromb Haemost 65 1991 377 381
22. A. Bernat, P. Hoffmann, and J.M. Herbert Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice Thromb Haemost 76 1996 715 719
23. D.S. Telgt, B.G. Macik, D.M. McCord, D.M. Monroe, and H.R. Roberts Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor Thromb Res 56 1989 603 609
24. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800
25. F. Dentali, C. Marchesi, M.G. Pierfranceschi, M. Crowther, D. Garcia, and E. Hylek Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis Thromb Haemost 106 2011 429 438